StreetInsider.com News Articles

Tarsus Pharmaceuticals CCO to depart for medical device CEO role

Mon, 13 Jul 2026 16:14:11 -0400

Tarsus Pharmaceuticals (NASDAQ: TARS) announced that Aziz Mottiwala will leave his position as Chief Commercial Officer on July 15, 2026, to become Chief Executive Officer of a public medical device company.

Tarsus Pharmaceuticals CCO to depart for medical device CEO role

Mon, 13 Jul 2026 16:14:11 -0400

Form 8-K Tarsus Pharmaceuticals, For: Jul 13

Mon, 13 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260713/26762582.html

Form 8-K Tarsus Pharmaceuticals, For: Jul 13

Mon, 13 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260713/26762582.html

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Mon, 13 Jul 2026 16:05:00 -0400

IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor.

Since joining Tarsus in 2021, Ms. Clase has played an integral role in the Company's evolution from a clinical-stage organization to a successful commercial biopharmaceutical company with one of the

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Mon, 13 Jul 2026 16:05:00 -0400

Since joining Tarsus in 2021, Ms. Clase has played an integral role in the Company's evolution from a clinical-stage organization to a successful commercial biopharmaceutical company with one of the

H.C. Wainwright Reiterates Buy Rating on Tarsus Pharmaceuticals (TARS)

Thu, 09 Jul 2026 06:48:17 -0400

H.C. Wainwright analyst Matt Caufield reiterated a Buy rating and $88.00 price target on Tarsus Pharmaceuticals (NASDAQ: TARS).

The analyst commented: 'We were encouraged to see the announcement of TARS’ acquisition of iRenix Medical (private) and the related late-stage asset IRX-101. We highlight that while the commercial platform continues to focus on robust XDEMVY growth in the topical treatment for Demodex blepharitis (DB) mites and eliminating the mites through targeting their GABA-gated chloride channels, the incorporation of IRX-101 into the pipeline importantly represents the company’s first strategic position in the retina, while addressing the front of the eye and right where

Form 8-K Tarsus Pharmaceuticals, For: Jul 06

Wed, 08 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260708/26747684.html

Form 8-K Tarsus Pharmaceuticals, For: Jul 06

Wed, 08 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260708/26747684.html

Tarsus acquires iRenix Medical for up to $565M in eye care deal

Wed, 08 Jul 2026 16:05:25 -0400

Tarsus Pharmaceuticals (NASDAQ: TARS) announced the acquisition of iRenix Medical, Inc., a privately held clinical-stage ophthalmic biopharmaceutical company, along with its investigational drug IRX-101, an ocular antiseptic in late-stage development.

Under the terms of the deal, Tarsus will pay approximately $75 million upfront, consisting of $37.5 million in cash and $37.5 million in Tarsus common stock, with potential milestone payments of up to $490 million tied to approval and commercialization.

IRX-101 is a stable aqueous chlorine dioxide solution being developed as an alternative to povidone-iodine, the antiseptic currently used in the majority of the more than 11 million intravitreal injections performed annually

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

Wed, 08 Jul 2026 16:05:00 -0400

IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care

Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and near-term path forward; transaction structured to align economics with future value creation

Tarsus to host investor conference call today, July 8, 2026, at 1:30 p.m. PT / 4:30 p.m. ET

IRVINE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the acquisition of iRenix Medical, Inc., a privately held, clinical-stage ophthalmic

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

Wed, 08 Jul 2026 16:05:00 -0400

IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care

Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and near-term path forward; transaction structured to align economics with future value creation

Tarsus to host investor conference call today, July 8, 2026, at 1:30 p.m. PT / 4:30 p.m. ET

IRVINE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the acquisition of iRenix Medical, Inc., a privately held, clinical-stage ophthalmic

Tarsus shares fall after short seller report

Wed, 01 Jul 2026 13:29:03 -0400

Investing.com -- Tarsus Pharmaceuticals saw its stock drop roughly 8% midday on Wednesday after short seller Culper Research disclosed a short position in the company.

Culper Research released a report stating it holds a short position in thecompany, whose only commercial product is XDEMVY, an eyedrop treatment for demodex blepharitis.

The short seller claims XDEMVY's growth has relied on a company-funded charitable foundation Medicare copay arrangement that raises Anti-Kickback Statute concerns. Culper argues XDEMVY's addressable market is approximately 20% of what Tarsus claims.

Culper alleges Tarsus has driven XDEMVY uptake by reducing Medicare patient copays through donations to a blepharitis fund operated

Culper Research short Tarsus Pharmaceuticals

Wed, 01 Jul 2026 13:05:45 -0400

(Updated - July 1, 2026 1:05 PM EDT)

Culper Research on Wednesday said it is short Tarsus Pharmaceuticals:

We are short Tarsus Pharmaceuticals, whose sole commercial product is XDEMVY, an eyedrop used to treat demodex blepharitis (“DB”). We believe that XDEMVY’s growth to date has relied on a Company-funded charitable foundation Medicare copay scheme that raises serious Anti-Kickback Statute (“AKS”) concerns, and that XDEMVY’s addressable market in DB is a fraction (~20%) of the Company’s claims. We expect Tarsus to unravel as its practices put the Company directly in Department of Justice (“DoJ”) crosshairs, XDEMVY revenues peak below $800 million at best

Culper Research short Tarsus Pharmaceuticals

Wed, 01 Jul 2026 13:05:45 -0400

(Updated - July 1, 2026 1:05 PM EDT)

Culper Research on Wednesday said it is short Tarsus Pharmaceuticals:

Form 4 Tarsus Pharmaceuticals, For: Jun 25 Filed by: Morrison Scott W